Newsletter summary

Text of news flash

May 6thAbeltr3reelThe overall performance of Hong Kong pharmaceutical stocks was strong, led by innovative drugs and CXO concept stocks. Pharmaceutical industryAbeltr3reelThe strong growth momentum has attracted the attention of investors in the secondary market. Among them, the CXO plate is extremely active, Zhaoyan New drugs (603127), Kanglong Huacheng (300759), Yao Ming Biology and Tiger Pharmaceuticals (300347) rose more than 6%, Kingsley rose more than 5%, Kellein (002821) rose strongly, up nearly 5%, and Yao Ming Kant (603259) rose more than 3%. Under the background of the rapid development of the pharmaceutical industry, the excellent performance of these CXO concept stocks undoubtedly provides new investment opportunities for investors.

On May 6, Hong Kong pharmaceutical stocks rose as a whole, with innovative drugs and CXO performing the most. ]

The field of innovative drugs is also favored, with broad development prospects and huge market potential. With the progress of science and technology and the support of policies, the research and application of innovative drugs are gradually becoming a new engine for the development of the industry.

CXO is contract research and development, production and sales services. In recent years, with the development of the pharmaceutical industry, the CXO industry has also shown a trend of rapid development. Its business covers R & D, production, sales and other links, providing one-stop services for pharmaceutical enterprises, effectively reduce R & D costs, shorten R & D cycle, and improve R & D efficiency.

Investors in the secondary market continue to pay more attention to pharmaceutical stocks, which is not only due to the broad prospects of the pharmaceutical industry, but also closely related to its stable profitability and good growth. Investors can pay close attention to the developments in the industry and seize investment opportunities.